No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL-Reference-Cited by-同舟云学术

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL

Published:2015-11-25 Issue:1 Volume:63 Page:28-30
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

O'Brien Thomas R.¹,Feld Jordan J.²,Kottilil Shyam³,Pfeiffer Ruth M.⁴

Affiliation:

1. Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics; National Cancer Institute; Bethesda MD

2. Toronto Centre for Liver Disease; University of Toronto; Toronto Canada

3. Division of Clinical Care and Research, Institute of Human Virology; University of Maryland School of Medicine; Baltimore MD

4. Biostatistics Branch, Division of Cancer Epidemiology and Genetics; National Cancer Institute; Bethesda MD

Publisher

Wiley

Subject

Hepatology

Reference8 articles.

1. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis;Kowdley;N Engl J Med,2014

2. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C;O'Brien;Open Forum Infect Dis,2014

3. Therapy for hepatitis C-the costs of success;Hoofnagle;N Engl J Med,2014

4. US Food Drug Administration Center for Drug Evaluation and Research Sofosbuvir and ledipasvir fixed-dose combination. Statistical Review and Evaluation, NDA 205834 2014

5. EASL recommendations on treatment of hepatitis C 2015;European Association for the Study of the Liver;J Hepatol,2015

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C;Journal of Infection;2024-11

2. IFNL4 Genotype Frequencies in Asian Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured;Journal of Interferon & Cytokine Research;2023-09-01

3. Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection;Frontiers in Immunology;2019-06-27

4. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression;Gastroenterology;2019-01

5. Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL;Digestive Diseases and Sciences;2018-09-27